Streetbeat News

Analyst Ratings

KIDS

OrthoPediatrics (NASDAQ:KIDS) reported Q3 losses of $(0.13) per share, beating the analyst consensus estimate of $(0.22) by 40.91%. However, the company's quarterly sales of $39.97 million missed the analyst consensus estimate of $40.37 million by 0.99%. This represents a 160% increase in losses and a 14.37% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 9:25 pm

LLY

Eli Lilly and Company (LLY) shares traded higher on Monday following the company's better-than-expected Q3 earnings report. The company reported earnings of 10 cents per share, beating the analyst consensus estimate of losses of 15 cents, and sales of $9.50 billion, beating the estimate of $8.95 billion. However, the company reduced its full-year 2023 revenue guidance. Morgan Stanley analyst David Phung maintained Eli Lilly with an Overweight and raised the price target from $673 to $722.

Portfolio Pulse from Ryan Gustafson

November 06, 2023 | 9:20 pm

SIBN

SI-BONE (NASDAQ:SIBN) reported Q3 2023 earnings per share (EPS) of $(0.25), beating the analyst consensus estimate of $(0.34) by 26.47%. This is a 39.02% increase over losses from the same period last year. The company also reported quarterly sales of $34.01 million, beating the analyst consensus estimate of $32.38 million by 5.05%, a 28.68% increase from the same period last year.

Portfolio Pulse from vinayak@benzinga.com

November 06, 2023 | 9:19 pm

MED

Medifast reported Q3 2023 earnings of $2.12 per share, beating the analyst consensus estimate of $1.06 by 100%. However, this is a 36.14% decrease from the same period last year. The company also reported quarterly sales of $235.87 million, beating the estimate of $232.10 million by 1.62%, but this is a 39.58% decrease from the same period last year.

Portfolio Pulse from saritha@benzinga.com

November 06, 2023 | 9:18 pm

VRTX

Vertex Pharmaceuticals reported Q3 earnings of $4.08 per share, beating the analyst consensus estimate of $3.98 by 2.51%. This is a 1.75% increase from the same period last year. However, the company's quarterly sales of $2.48 billion missed the analyst consensus estimate of $2.50 billion by 0.64%, though it's a 6.43% increase from last year.

Portfolio Pulse from bharat@benzinga.com

November 06, 2023 | 9:11 pm

TASK

TaskUs (NASDAQ:TASK) reported Q3 adjusted earnings of $0.32 per share, beating the analyst consensus estimate of $0.29 by 10.34%. However, this is an 8.57% decrease from the same period last year. The company also reported quarterly sales of $225.63 million, surpassing the analyst consensus estimate of $220.78 million by 2.19%, but marking a 2.80% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 9:05 pm

T

AT&T (NYSE:T) has received a mix of analyst ratings in the last quarter, with 2 bullish, 1 somewhat bullish, and 3 indifferent. The average price target is $17.25, which is higher than the current price of $15.7245. However, this average has decreased by 6.76% from the previous average price target of $18.50.

Portfolio Pulse from Benzinga Insights

November 06, 2023 | 9:00 pm

PAA

In the last quarter, Plains All American (NASDAQ:PAA) received mixed analyst ratings with 1 bullish, 1 indifferent, and 2 bearish. The company's average 12-month price target is $16.25, up 4.84% from the previous average of $15.50.

Portfolio Pulse from Benzinga Insights

November 06, 2023 | 9:00 pm

SGMO

Over the past 3 months, 9 analysts have published their opinion on Sangamo Therapeutics (NASDAQ:SGMO) stock. The average price target for the stock is $5.22, a decrease of 38.08% from the previous average price target of $8.43. The majority of the analysts are bullish on the stock.

Portfolio Pulse from Benzinga Insights

November 06, 2023 | 9:00 pm

SBUX

In the last quarter, Starbucks (NASDAQ:SBUX) received 10 analyst ratings, with most being indifferent. The average 12-month price target for the company is $106.7, representing a 3.0% decrease from the previous average price target of $110.00.

Portfolio Pulse from Benzinga Insights

November 06, 2023 | 9:00 pm